BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 32821962)

  • 21. Prospective comparative diagnostic accuracy evaluation of dynamic contrast-enhanced (DCE) vs. dynamic susceptibility contrast (DSC) MR perfusion in differentiating tumor recurrence from radiation necrosis in treated high-grade gliomas.
    Zakhari N; Taccone MS; Torres CH; Chakraborty S; Sinclair J; Woulfe J; Jansen GH; Cron GO; Thornhill RE; McInnes MDF; Nguyen TB
    J Magn Reson Imaging; 2019 Aug; 50(2):573-582. PubMed ID: 30614146
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Differentiation between glioblastoma and primary CNS lymphoma: application of DCE-MRI parameters based on arterial input function obtained from DSC-MRI.
    Kang KM; Choi SH; Chul-Kee P; Kim TM; Park SH; Lee JH; Lee ST; Hwang I; Yoo RE; Yun TJ; Kim JH; Sohn CH
    Eur Radiol; 2021 Dec; 31(12):9098-9109. PubMed ID: 34003350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Differentiation of primary central nervous system lymphoma and high-grade glioma with dynamic susceptibility contrast-enhanced perfusion magnetic resonance imaging.
    Liao W; Liu Y; Wang X; Jiang X; Tang B; Fang J; Chen C; Hu Z
    Acta Radiol; 2009 Mar; 50(2):217-25. PubMed ID: 19096950
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Differentiating primary central nervous system lymphoma from glioblastoma by time-dependent diffusion using oscillating gradient.
    Kamimura K; Nakano T; Hasegawa T; Nakajo M; Yamada C; Kamimura Y; Akune K; Ejima F; Ayukawa T; Nagano H; Takumi K; Nakajo M; Higa N; Yonezawa H; Hanaya R; Kirishima M; Tanimoto A; Iwanaga T; Imai H; Feiweier T; Yoshiura T
    Cancer Imaging; 2023 Nov; 23(1):114. PubMed ID: 38037172
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Primary central nervous system lymphoma and atypical glioblastoma: differentiation using the initial area under the curve derived from dynamic contrast-enhanced MR and the apparent diffusion coefficient.
    Choi YS; Lee HJ; Ahn SS; Chang JH; Kang SG; Kim EH; Kim SH; Lee SK
    Eur Radiol; 2017 Apr; 27(4):1344-1351. PubMed ID: 27436023
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Permeability measurement using dynamic susceptibility contrast magnetic resonance imaging enhances differential diagnosis of primary central nervous system lymphoma from glioblastoma.
    Lee JY; Bjørnerud A; Park JE; Lee BE; Kim JH; Kim HS
    Eur Radiol; 2019 Oct; 29(10):5539-5548. PubMed ID: 30877463
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Quantitative apparent diffusion coefficients in the characterization of brain tumors and associated peritumoral edema.
    Server A; Kulle B; Maehlen J; Josefsen R; Schellhorn T; Kumar T; Langberg CW; Nakstad PH
    Acta Radiol; 2009 Jul; 50(6):682-9. PubMed ID: 19449234
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Multiparametric MRI in differentiating solitary brain metastasis from high-grade glioma: diagnostic value of the combined use of diffusion-weighted imaging, dynamic susceptibility contrast imaging, and magnetic resonance spectroscopy parameters.
    Aslan K; Gunbey HP; Tomak L; Incesu L
    Neurol Neurochir Pol; 2019; 53(3):227-237. PubMed ID: 31180131
    [TBL] [Abstract][Full Text] [Related]  

  • 29. The performance of MR perfusion-weighted imaging for the differentiation of high-grade glioma from primary central nervous system lymphoma: A systematic review and meta-analysis.
    Xu W; Wang Q; Shao A; Xu B; Zhang J
    PLoS One; 2017; 12(3):e0173430. PubMed ID: 28301491
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Diffusional kurtosis imaging for differentiating between high-grade glioma and primary central nervous system lymphoma.
    Pang H; Ren Y; Dang X; Feng X; Yao Z; Wu J; Yao C; Di N; Ghinda DC; Zhang Y
    J Magn Reson Imaging; 2016 Jul; 44(1):30-40. PubMed ID: 26588793
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Utility of arterial spin labelling MRI for discriminating atypical high-grade glioma from primary central nervous system lymphoma.
    Di N; Cheng W; Chen H; Zhai F; Liu Y; Mu X; Chu Z; Lu N; Liu X; Wang B
    Clin Radiol; 2019 Feb; 74(2):165.e1-165.e9. PubMed ID: 30415766
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Differentiation between high-grade gliomas and solitary brain metastases: a comparison of five diffusion-weighted MRI models.
    Mao J; Zeng W; Zhang Q; Yang Z; Yan X; Zhang H; Wang M; Yang G; Zhou M; Shen J
    BMC Med Imaging; 2020 Nov; 20(1):124. PubMed ID: 33228564
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Myo-inositol concentration in MR spectroscopy for differentiating high grade glioma from primary central nervous system lymphoma.
    Nagashima H; Sasayama T; Tanaka K; Kyotani K; Sato N; Maeyama M; Kohta M; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    J Neurooncol; 2018 Jan; 136(2):317-326. PubMed ID: 29143277
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Conventional MR and DW imaging findings of cerebellar primary CNS lymphoma: comparison with high-grade glioma.
    He YX; Qu CX; He YY; Shao J; Gao Q
    Sci Rep; 2020 Jun; 10(1):10007. PubMed ID: 32561819
    [TBL] [Abstract][Full Text] [Related]  

  • 35. MRI as a diagnostic biomarker for differentiating primary central nervous system lymphoma from glioblastoma: A systematic review and meta-analysis.
    Suh CH; Kim HS; Jung SC; Park JE; Choi CG; Kim SJ
    J Magn Reson Imaging; 2019 Aug; 50(2):560-572. PubMed ID: 30637843
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Grading of Glioma: combined diagnostic value of amide proton transfer weighted, arterial spin labeling and diffusion weighted magnetic resonance imaging.
    Kang XW; Xi YB; Liu TT; Wang N; Zhu YQ; Wang XR; Guo F
    BMC Med Imaging; 2020 May; 20(1):50. PubMed ID: 32408867
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Differentiating IDH-mutant astrocytomas and 1p19q-codeleted oligodendrogliomas using DSC-PWI: high performance through cerebral blood volume and percentage of signal recovery percentiles.
    Pons-Escoda A; Garcia-Ruiz A; Naval-Baudin P; Martinez-Zalacain I; Castell J; Camins A; Vidal N; Bruna J; Cos M; Perez-Lopez R; Oleaga L; Warnert E; Smits M; Majos C
    Eur Radiol; 2024 Jan; ():. PubMed ID: 38282078
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Dynamic contrast-enhanced and dynamic susceptibility contrast perfusion MR imaging for glioma grading: Preliminary comparison of vessel compartment and permeability parameters using hotspot and histogram analysis.
    Santarosa C; Castellano A; Conte GM; Cadioli M; Iadanza A; Terreni MR; Franzin A; Bello L; Caulo M; Falini A; Anzalone N
    Eur J Radiol; 2016 Jun; 85(6):1147-56. PubMed ID: 27161065
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Spatial discrimination of glioblastoma and treatment effect with histologically-validated perfusion and diffusion magnetic resonance imaging metrics.
    Prah MA; Al-Gizawiy MM; Mueller WM; Cochran EJ; Hoffmann RG; Connelly JM; Schmainda KM
    J Neurooncol; 2018 Jan; 136(1):13-21. PubMed ID: 28900832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical Value of Vascular Permeability Estimates Using Dynamic Susceptibility Contrast MRI: Improved Diagnostic Performance in Distinguishing Hypervascular Primary CNS Lymphoma from Glioblastoma.
    Lee B; Park JE; Bjørnerud A; Kim JH; Lee JY; Kim HS
    AJNR Am J Neuroradiol; 2018 Aug; 39(8):1415-1422. PubMed ID: 30026384
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.